Integrated network pharmacology and molecular docking analyses indicated that compound <b>3</b> exerts potential anti-gastric-cancer effects by modulating multiple cancer-related signaling pathways, with EGFR identified as a potential target of compound <b>3</b>. The gene discussed is EGFR; the disease is cancer.